Matching articles for "Shingrix"

Influenza Vaccine for 2024-2025

   
The Medical Letter on Drugs and Therapeutics • September 16, 2024;  (Issue 1711)
Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines available in the US for the 2024-2025 season...
Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines available in the US for the 2024-2025 season are listed in Table 2.
Med Lett Drugs Ther. 2024 Sep 16;66(1711):145-50 | Show Full IntroductionHide Full Introduction

Influenza Vaccine for 2023-2024

   
The Medical Letter on Drugs and Therapeutics • October 16, 2023;  (Issue 1687)
Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines that are available in the US for the 2023-2024...
Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines that are available in the US for the 2023-2024 season are listed in Table 2.
Med Lett Drugs Ther. 2023 Oct 16;65(1687):161-6 | Show Full IntroductionHide Full Introduction

Adult Immunization

   
The Medical Letter on Drugs and Therapeutics • October 17, 2022;  (Issue 1661)
The Advisory Committee on Immunization Practices (ACIP) recommends use of certain vaccines in adults residing in the US. Routine childhood immunization has reduced the overall incidence of some of these...
The Advisory Committee on Immunization Practices (ACIP) recommends use of certain vaccines in adults residing in the US. Routine childhood immunization has reduced the overall incidence of some of these vaccine-preventable diseases, but many adults remain susceptible. Recommendations for vaccination against COVID-19, seasonal influenza, and monkeypox and vaccination of travelers have been reviewed separately.
Med Lett Drugs Ther. 2022 Oct 17;64(1661):161-8 | Show Full IntroductionHide Full Introduction

Adult Immunization

   
The Medical Letter on Drugs and Therapeutics • October 17, 2022;  (Issue 1661)
The Advisory Committee on Immunization Practices (ACIP) recommends use of certain vaccines in adults residing in the US. Routine childhood immunization has reduced the overall incidence of some of these...
The Advisory Committee on Immunization Practices (ACIP) recommends use of certain vaccines in adults residing in the US. Routine childhood immunization has reduced the overall incidence of some of these vaccine-preventable diseases, but many adults remain susceptible. Recommendations for vaccination against COVID-19, seasonal influenza, and monkeypox and vaccination of travelers have been reviewed separately.
Med Lett Drugs Ther. 2022 Oct 17;64(1661):161-8 | Show Full IntroductionHide Full Introduction

Expanded Table: Some Vaccines for Adults (online only)

   
The Medical Letter on Drugs and Therapeutics • October 17, 2022;  (Issue 1661)
...
Med Lett Drugs Ther. 2022 Oct 17;64(1661):e170-3 | Show Full IntroductionHide Full Introduction

Influenza Vaccine for 2022-2023

   
The Medical Letter on Drugs and Therapeutics • October 3, 2022;  (Issue 1660)
Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines that are available in the US for the 2022-2023...
Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines that are available in the US for the 2022-2023 season are listed in Table 2.
Med Lett Drugs Ther. 2022 Oct 3;64(1660):153-7 | Show Full IntroductionHide Full Introduction

Influenza Vaccine for 2021-2022

   
The Medical Letter on Drugs and Therapeutics • October 4, 2021;  (Issue 1634)
Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication.1 Available influenza vaccines for the 2021-2022 season are listed in Table...
Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication.1 Available influenza vaccines for the 2021-2022 season are listed in Table 2.
Med Lett Drugs Ther. 2021 Oct 4;63(1634):153-7 | Show Full IntroductionHide Full Introduction

In Brief: Shingrix for Immunocompromised Adults

   
The Medical Letter on Drugs and Therapeutics • August 23, 2021;  (Issue 1631)
The FDA has licensed the adjuvanted, recombinant varicella zoster virus (VZV) vaccine Shingrix (GSK) for prevention of herpes zoster (shingles) in adults of any age who are or will be at elevated risk...
The FDA has licensed the adjuvanted, recombinant varicella zoster virus (VZV) vaccine Shingrix (GSK) for prevention of herpes zoster (shingles) in adults of any age who are or will be at elevated risk because of disease- or therapy-induced immunodeficiency or immunosuppression. Shingrix has been licensed for herpes zoster prevention in adults ≥50 years old since 2017.1 It is the only VZV vaccine currently available in the US; Zostavax, a live-attenuated VZV vaccine, was withdrawn from the market in 2020.
Med Lett Drugs Ther. 2021 Aug 23;63(1631):129 | Show Full IntroductionHide Full Introduction

Influenza Vaccine for 2020-2021

   
The Medical Letter on Drugs and Therapeutics • September 21, 2020;  (Issue 1607)
Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Vaccination of all eligible persons can reduce the prevalence of influenza illness...
Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Vaccination of all eligible persons can reduce the prevalence of influenza illness and symptoms that might be confused with those of COVID-19. Available vaccines and recommendations for specific patient populations for the 2020-2021 season are listed in Tables 2 and 3. Lower rates of influenza illness have been observed this season in the Southern Hemisphere, probably because of masking, social distancing, school closures, and travel restrictions.
Med Lett Drugs Ther. 2020 Sep 21;62(1607):145-50 | Show Full IntroductionHide Full Introduction

Influenza Vaccine for 2019-2020

   
The Medical Letter on Drugs and Therapeutics • October 21, 2019;  (Issue 1583)
Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Available vaccines and recommendations for specific patient populations for the...
Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Available vaccines and recommendations for specific patient populations for the 2019-2020 season are listed in Tables 2 and 3.
Med Lett Drugs Ther. 2019 Oct 21;61(1583):161-6 | Show Full IntroductionHide Full Introduction

Adult Immunization

   
The Medical Letter on Drugs and Therapeutics • May 7, 2018;  (Issue 1546)
The US Advisory Committee on Immunization Practices (ACIP) recommends routine use of the following vaccines in adults residing in the US: influenza, tetanus/diphtheria alone (Td) and in combination with...
The US Advisory Committee on Immunization Practices (ACIP) recommends routine use of the following vaccines in adults residing in the US: influenza, tetanus/diphtheria alone (Td) and in combination with acellular pertussis (Tdap), measles/mumps/rubella (MMR), varicella (VAR), herpes zoster (RZV; ZVL), human papillomavirus (HPV), and pneumococcal conjugate (PCV13) and polysaccharide (PPSV23) vaccines. For adults with certain medical conditions or occupational, behavioral, or other risk factors, hepatitis A (HepA), hepatitis B (HepB), meningococcal (MenACWY; MenB), and Haemophilus influenzae type b (Hib) vaccines are also recommended. Recommendations for vaccination against seasonal influenza and vaccination of travelers are reviewed separately.
Med Lett Drugs Ther. 2018 May 7;60(1546):73-82 | Show Full IntroductionHide Full Introduction

Expanded Table: Some Vaccines Recommended for Use in Adults (online only)

   
The Medical Letter on Drugs and Therapeutics • May 7, 2018;  (Issue 1546)
...
View the Expanded Table: Some Vaccines Recommended for Use in Adults
Med Lett Drugs Ther. 2018 May 7;60(1546):e82-5 | Show Full IntroductionHide Full Introduction

Shingrix - An Adjuvanted, Recombinant Herpes Zoster Vaccine

   
The Medical Letter on Drugs and Therapeutics • December 4, 2017;  (Issue 1535)
The FDA has approved an adjuvanted, recombinant varicella zoster virus (VZV) vaccine (Shingrix – GSK) for prevention of herpes zoster (shingles) in adults ≥50 years old. Shingrix is the second herpes...
The FDA has approved an adjuvanted, recombinant varicella zoster virus (VZV) vaccine (Shingrix – GSK) for prevention of herpes zoster (shingles) in adults ≥50 years old. Shingrix is the second herpes zoster vaccine to be approved in the US; Zostavax, a live-attenuated VZV vaccine approved for the same indication, has been available since 2006.
Med Lett Drugs Ther. 2017 Dec 4;59(1535):195-6 | Show Full IntroductionHide Full Introduction